» Articles » PMID: 26876983

Regulators of Androgen Action Resource: a One-stop Shop for the Comprehensive Study of Androgen Receptor Action

Overview
Specialty Biology
Date 2016 Feb 16
PMID 26876983
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Androgen receptor (AR) is a ligand-activated transcription factor that is the main target for treatment of non-organ-confined prostate cancer (CaP). Failure of life-prolonging AR-targeting androgen deprivation therapy is due to flexibility in steroidogenic pathways that control intracrine androgen levels and variability in the AR transcriptional output. Androgen biosynthesis enzymes, androgen transporters and AR-associated coregulators are attractive novel CaP treatment targets. These proteins, however, are characterized by multiple transcript variants and isoforms, are subject to genomic alterations, and are differentially expressed among CaPs. Determining their therapeutic potential requires evaluation of extensive, diverse datasets that are dispersed over multiple databases, websites and literature reports. Mining and integrating these datasets are cumbersome, time-consuming tasks and provide only snapshots of relevant information. To overcome this impediment to effective, efficient study of AR and potential drug targets, we developed the Regulators of Androgen Action Resource (RAAR), a non-redundant, curated and user-friendly searchable web interface. RAAR centralizes information on gene function, clinical relevance, and resources for 55 genes that encode proteins involved in biosynthesis, metabolism and transport of androgens and for 274 AR-associated coregulator genes. Data in RAAR are organized in two levels: (i) Information pertaining to production of androgens is contained in a 'pre-receptor level' database, and coregulator gene information is provided in a 'post-receptor level' database, and (ii) an 'other resources' database contains links to additional databases that are complementary to and useful to pursue further the information provided in RAAR. For each of its 329 entries, RAAR provides access to more than 20 well-curated publicly available databases, and thus, access to thousands of data points. Hyperlinks provide direct access to gene-specific entries in the respective database(s). RAAR is a novel, freely available resource that provides fast, reliable and easy access to integrated information that is needed to develop alternative CaP therapies. Database URL: http://www.lerner.ccf.org/cancerbio/heemers/RAAR/search/.

Citing Articles

An unbiased seed-based RNAi selection screen identifies small RNAs that inhibit androgen signaling and prostate cancer cell growth.

Corbin J, Georgescu C, Wang L, Wren J, Bieniasz M, Xu C Mol Ther Nucleic Acids. 2023; 33:257-272.

PMID: 37554515 PMC: 10404560. DOI: 10.1016/j.omtn.2023.06.021.


Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.

Varisli L, Tolan V, Cen J, Vlahopoulos S, Cen O Oncol Res. 2023; 30(3):137-155.

PMID: 37305018 PMC: 10208071. DOI: 10.32604/or.2022.026074.


AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways.

Tortorella E, Giantulli S, Sciarra A, Silvestri I Int J Mol Sci. 2023; 24(3).

PMID: 36768370 PMC: 9917224. DOI: 10.3390/ijms24032046.


The role of ubiquitination in spinal and bulbar muscular atrophy.

Sengupta M, Pluciennik A, Merry D Front Mol Neurosci. 2022; 15:1020143.

PMID: 36277484 PMC: 9583669. DOI: 10.3389/fnmol.2022.1020143.


Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer.

Mao Y, Yang G, Li Y, Liang G, Xu W, Hu M Cancers (Basel). 2022; 14(15).

PMID: 35954408 PMC: 9367587. DOI: 10.3390/cancers14153744.


References
1.
Chia K, OBrien M, Brown M, Lim E . Targeting the androgen receptor in breast cancer. Curr Oncol Rep. 2015; 17(2):4. DOI: 10.1007/s11912-014-0427-8. View

2.
Karantanos T, Evans C, Tombal B, Thompson T, Montironi R, Isaacs W . Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2014; 67(3):470-9. PMC: 5301306. DOI: 10.1016/j.eururo.2014.09.049. View

3.
Chen E, Sowalsky A, Gao S, Cai C, Voznesensky O, Schaefer R . Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2014; 21(6):1273-80. PMC: 4359958. DOI: 10.1158/1078-0432.CCR-14-1220. View

4.
Heemers H, Tindall D . Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007; 28(7):778-808. DOI: 10.1210/er.2007-0019. View

5.
Locke J, Guns E, Lubik A, Adomat H, Hendy S, Wood C . Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008; 68(15):6407-15. DOI: 10.1158/0008-5472.CAN-07-5997. View